# CHK1 inhibitor payloads

Source: https://onco.cc/terms/chk1-inhibitor-payloads/  
OnCo record `chk1-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A CHK1-inhibitor conjugate carries a drug that interferes with a replication-stress checkpoint. A published conference abstract reports a HER2-directed preclinical example.

## Summary

CHK1 inhibition is the cargo mechanism only when the inhibitor is physically attached to the conjugate. The AACR 2026 abstract describes engineered-cysteine trastuzumab, a cleavable linker and a CHK1-inhibitor payload. The investigators tested cells and a HER2-positive breast-cancer xenograft model. This establishes a publicly described payload design and model experiment, separate from giving an oral checkpoint inhibitor alongside another ADC. It does not establish human safety, benefit after a TOP1 ADC or a treatment-selection rule.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: CHK1i ADC payloads; checkpoint kinase 1 inhibitor cargo

## Notes

- The antibody delivery antigen and the payload’s checkpoint target answer different questions. The proposed advantage depends on sufficient intracellular release and checkpoint dependence, not a HER2 or replication-stress label alone. The conference abstract reports limited model safety observations; lack of mouse weight loss cannot establish human marrow safety or a clinical therapeutic window.
- An earlier 2020 study attached the checkpoint inhibitor AZD7762 to an antibody. The conjugate recognized the tested cell-surface target but lacked efficacy in that delivery experiment; the investigators pursued protease-activated cell-penetrating peptides instead. Physical attachment and target binding therefore did not establish a useful intracellular effect. This negative result does not establish that every CHK1-directed conjugate must fail.
- The 2026 A067 conference abstract screened exatecan with prexasertib in cancer-cell and blood-progenitor assays. It proposes a candidate pair for dual-payload development; the abstract does not itself document both chemicals attached to a tested antibody. Pairwise synergy, a constructed dual-cargo product and a patient therapeutic window are separate claims.
- NCT02124148 lists prexasertib and cetuximab as separately administered drugs with different schedules. It is not evidence of a cetuximab conjugate carrying a CHK1 inhibitor. Registry design, observed pharmacodynamic changes and patient outcomes also require separate interpretation.

## Sources

- Halazonetis et al.: CHK1-inhibitor conjugate, AACR 2026 abstract 1714: https://doi.org/10.1158/1538-7445.am2026-1714
- 2020 antibody versus peptide radiosensitizer delivery experiment: https://pubmed.ncbi.nlm.nih.gov/32304937/
- Meng et al.: exatecan/prexasertib pair screening, AACR D3 abstract A067 (2026): https://doi.org/10.1158/1557-3265.d32026-a067
- ClinicalTrials.gov: separate prexasertib/cetuximab administration in NCT02124148: https://clinicaltrials.gov/study/NCT02124148

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [ATR and CHK1 inhibitors](https://onco.cc/technologies/atr-chk1-inhibitors/)
- pathways: [DNA replication stress](https://onco.cc/pathways/replication-stress/)
- terms: [ADC analytes and exposure](https://onco.cc/terms/adc-analytes-and-exposure/), [Synthetic lethality](https://onco.cc/terms/synthetic-lethality/)
- targets: [CHEK1](https://onco.cc/targets/chek1/)

---
JSON: https://onco.cc/api/v1/entities/chk1-inhibitor-payloads.json